Multiple clinical trials are now studying post-TIL anti-CTLA-4 or anti-PD-1 therapies in advanced or metastatic cutaneous melanoma, HNSCC, NSCLC, or cervical cancers (NCT02278887, NCT03645928, NCT03108495). Here, PDCD1 is linked to head and neck squamous cell carcinoma.